A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of CNTO136 Following a Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects.
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2013
At a glance
- Drugs Sirukumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 06 Oct 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2009 Actual patient number (62) added as reported by ClinicalTrials.gov.